Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs UnitedHealth Group Inc (UNH) Price & Performance

Davita IncTrade
UnitedHealth Group IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs UnitedHealth Group Inc — how do they compare? Davita Inc trades at $230.54 (market cap $14.92B), while UnitedHealth Group Inc trades at $421.85 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 26.1× Davita Inc's market cap, and UnitedHealth Group Inc pays a 2.16% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAUNH
Market Cap
$14.92B$389.68B
Sector
HealthHealth
52-Week High
$235.71$431.68
52-Week Low
$103.87$237.77
Enterprise Value
$27.47B$436.36B
Dividend Yield
2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.

The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.

UnitedHealth Group Inc

UnitedHealth Group (UNH) trades at $429.09, up 1.05% on the day, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding expectations, and a dividend of $2.32 payable in June 2026. Revenue growth remains robust, reaching $447.57B in 2025, though net margins have compressed to 2.68%.

Outlook is positive due to aging demographics and tech innovation in healthcare, but risks include regulatory scrutiny and margin pressure. Wall Street's average price target of $438.33 suggests modest upside, supported by 82.69% buy ratings. Investors should weigh solid cash flow generation against legal challenges and rising debt levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About UnitedHealth Group Inc

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Read more on UNH